Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol Injection Long-term Safety Study
jRCT2080220578Phase 2
- Sponsor
- Abbott Laboratories
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by Abbott Laboratories.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on jRCT2080220578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220578.